Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar

doi:10.3748/wjg.v27.i46.7995

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 46

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5028)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

305

WORD

HTML

2502

Tables (1-6)

580

Sum=3474

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

425

Download

1129

Sum=1554

Dec 14, 2021 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Dec 14, 2021; 27(46): 7995-8009
Published online Dec 14, 2021. doi: 10.3748/wjg.v27.i46.7995

Table 5 Association of gastrointestinal symptoms with individual drugs, n (%)

	Azithromycin (n = 538)	HCQ (n = 540)	*Antibiotics (n =* 493)**	*Steroids (n =* 248)**	*RBV (n =* 91)**	*Tocilizumab (n =* 236)**	*L/r (n =* 340)**	*Oseltamivir (n =* 510)**
Diarrhea	78 (14.50)	79 (14.63)	70 (14.20)	37 (14.92)	24 (26.37)P < 0.001^a	35 (14.83)	44 (12.94)	75 (14.71)
Nausea	160 (29.74)	165 (30.60)	147 (29.82)	74 (29.84)	26 (8.57)	66 (27.97)	111 (32.65)P = 0.049^a	153 (30.00)
Vomiting	148 (27.51)	154 (28.52)P = 0.009^a	135 (27.38)	68 (27.42)	22 (24.18)	64 (27.12)	107 (31.47)P = 0.004^a	140 (27.45)
Epigastric pain	57 (10.59)	60 (11.11)	54 (10.95)	29 (11.69)	13 (14.29)	24 (10.17)	43 (12.65)P = 0.048^a	55 (10.78)
Anorexia	55 (10.22)	58 (10.74)	50 (10.14)	30 (12.10)	16 (17.58)P = 0.022^a	28 (11.86)	41 (12.06)	56 (10.98)
Any GI symptoms	208 (38.66)	209 (38.70)	191 (38.74)	95 (38.31)	41 (45.05)	92 (38.98)	138 (40.59)	194 (38.04)

^aStatistically significant P value.

HCQ: Hydroxychloroquine; RBV: Ribavirin; L/r: Lopinavir/ritonavir; GI: Gastrointestinal

Citation: Khan MU, Mushtaq K, Alsoub DH, Iqbal P, Ata F, Chaudhry HS, Iqbal F, Balaraju G, Maslamani MAA, Varughese B, Singh R, Ejji KA, Kaabi SA, Kamel YM, Butt AA. Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar. World J Gastroenterol 2021; 27(46): 7995-8009
URL: https://www.wjgnet.com/1007-9327/full/v27/i46/7995.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i46.7995